FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback